ArticleMicrobial cell factories2022
Optimizing the downstream MVA pathway using a combination optimization strategy to increase lycopene yield in Escherichia coli.
Article in Microbial cell factories, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Characterisation of metabolic burden in Pseudomonas putida reveals precursor limitation in heterologous lycopene production.Microbial cell factories · 2026Article
- Metabolic engineering of endogenous MEP pathway for enhanced lycopene production inSynthetic and systems biotechnology · 2026Article
- Exploring chromosomal position effects for predictable tuning of metabolic pathways in yeast.Nucleic acids research · 2026Article
- CyanoConstruct: simple platform for cyanobacterial expression construct assembly and translational tuning.BMC biotechnology · 2026Article
- Characterization of Nerolidol Synthase (VsNES1) fromPlants (Basel, Switzerland) · 2025Article
- Reusable combinatorial libraries with high diversity for efficient multi-gene expression optimization in Escherichia coli.World journal of microbiology & biotechnology · 2025Article
- A cross-species inducible system for enhanced protein expression and multiplexed metabolic pathway fine-tuning in bacteria.Nucleic acids research · 2025Article
- Automated characterization and analysis of expression compatibility between regulatory sequences and metabolic genes inSynthetic and systems biotechnology · 2024Article
- Reconstitution of the Mevalonate Pathway for Improvement of Isoprenoid Production and Industrial Applicability inJournal of microbiology and biotechnology · 2024Article
- Recent advances in lycopene and germacrene a biosynthesis and their role as antineoplastic drugs.World journal of microbiology & biotechnology · 2024Review
- Model-guided metabolic rewiring to bypass pyruvate oxidation for pyruvate derivative synthesis by minimizing carbon loss.mSystems · 2024Article
- A Light-Driven In Vitro Enzymatic Biosystem for the Synthesis of α-Farnesene from Methanol.Biodesign research · 2024Article
- Transcription regulation strategies in methylotrophs: progress and challenges.Bioresources and bioprocessing · 2022Review
- Correction to: Optimizing the downstream MVA pathway using a combination optimization strategy to increase lycopene yield in Escherichia coli.Microbial cell factories · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLycopene is increasing in demand due to its widespread use in the pharmaceutical and food industries. Metabolic engineering and synthetic biology technologies have been widely used to overexpress the heterologous mevalonate pathway and lycopene pathway in Escherichia coli to produce lycopene. However, due to the tedious metabolic pathways and complicated metabolic background, optimizing the lycopene synthetic pathway using reasonable design approaches becomes difficult.
resultsIn this study, the heterologous lycopene metabolic pathway was introduced into E. coli and divided into three modules, with mevalonate and DMAPP serving as connecting nodes. The module containing the genes (MVK, PMK, MVD, IDI) of downstream MVA pathway was adjusted by altering the expression strength of the four genes using the ribosome binding sites (RBSs) library with specified strength to improve the inter-module balance. Three RBS libraries containing variably regulated MVK, PMK, MVD, and IDI were constructed based on different plasmid backbones with the variable promoter and replication origin. The RBS library was then transformed into engineered E. coli BL21(DE3) containing pCLES and pTrc-lyc to obtain a lycopene producer library and employed high-throughput screening based on lycopene color to obtain the required metabolic pathway. The shake flask culture of the selected high-yield strain resulted in a lycopene yield of 219.7 mg/g DCW, which was 4.6 times that of the reference strain.
conclusionA strain capable of producing 219.7 mg/g DCW with high lycopene metabolic flux was obtained by fine-tuning the expression of the four MVA pathway enzymes and visual selection. These results show that the strategy of optimizing the downstream MVA pathway through RBS library design can be effective, which can improve the metabolic flux and provide a reference for the synthesis of other terpenoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.